Further, PSMA therapy, a promising treatment for advanced PCa, is a type of radionuclide therapy that uses a radioactive isotope (lutetium-177) attached to a molecule that specifically binds to the prostate-specific membrane antigen (PSMA) to deliver radioactive particles directly to cancer cells. Here, FOLH1 is linked to cancer.